Industry Overview:
The Global Intranasal Drug Delivery Devices market is estimated to reach USD 1,897.0 million in 2025, reflecting a growth rate of 9.7%. The market growth is driven by the rising prevalence of the local and systematic diseases involving rhinitis, upsurge in the preference for the non-invasive procedures, rising cases of neurological disorders escalates the demand for the nose-to-brain delivery systems. The MedTech manufacturers are focusing on the advancements in intranasal drug delivery devices and its medications including mucoadhesive formulations, nose-to-brain delivery platforms, nano formulations, auto-actuations, introduction of the biodegradable materials in devices which leads to the production of high-quality devices and increases the utilisation proportion which results in to the market expansion.
________________________________________
Industry Insights: Scale, Segments, and Shifts
• Market Size & Growth: The global Intranasal Drug Delivery Devices market is projected to reach USD 4,831.6 million by 2035, registering a CAGR of 9.8% between 2025 and 2035.
• Segment Analysis: Liquid nasal spray devices segment makes up about 43% of the market share owing to the rapid drug absorption, non-invasive, patient convenience, and greater bioavailability and powder nasal devices is expected to grow at the fastest pace.
• Regional Highlights: With growing prevalence of the chronic respiratory diseases and allergic conditions, the North America holds about 39% of the overall market share in 2024. Asia Pacific is witnessing the fastest share attributed to the robust and sophisticated healthcare infrastructure.
• Competitive Landscape: The market is moderately consolidated with competitors like Aegis Therapeutics LLC, Aptar Pharma Group, AstraZeneca Plc, Becton, Dickinson and Company, GlaxoSmithKline Plc, H&T Presspart Manufacturing Ltd., Johnson & Johnson, Inc., Merck & Co., Inc., Neurelis Inc, Novartis AG, OptiNose Inc, Pfizer Inc., Teleflex Incorporated, and Vectura Group Plc.
________________________________________
Factors Shaping the Next Decade
• Market Gaps / Restraints: The several factors that restrains the market are poor permeability of larger molecules, short shelf life of liquid formulations, stability issues and stringent regulatory regulations.
• Key Trends and Innovations: The intranasal drug delivery devices market is escalating with advancements including needle free vaccination, nanoformulations, mucoadhesive formulations, bi-directional spray devices, auto actuated devices, inclusion of the biodegradable polymers in devices to enhance the compatibility.
• Potential Opportunities: Intranasal drug administration offers rapid, needle-free treatments, enhancing patient comfort and compliance. Innovations in dry powder and mucoadhesive formulations increase drug stability and absorption, while advancements in nose-to-brain delivery present new treatment options for neurological disorders. smart nasal devices capable of tracking dosages and connecting to digital platforms pave the way for more personalized and convenient healthcare solutions in the future.
________________________________________
Recent Industry Updates:
• August 2025: Aptar Pharma has introduced a significant advancement in sustainable pharmaceutical packaging with the Freepod nasal spray pump, now produced using mass balance bio-based resins. This pump, utilized in Haleon's Otrivin products, is the first Aptar delivery system to be globally commercialized.
• April 2025: Satsuma Pharmaceuticals, Inc. announced that the U.S. FDA has approved the 505(b)(2) New Drug Application for Atzumi™ (dihydroergotamine nasal powder) for the acute treatment of migraine in adults, with or without aura. Atzumi was formerly known as STS101.
• February 2025: Zeteo Biomedical LLC has launched the ZTech-P CygnusMR™ and CygnusSDX™ delivery devices for precise nasal and nose-to-brain dosing of dry powder drugs and biologics, enhance the development and deployment of nasal combination products across various therapeutic applications.
• January 2025: Lonza announced the partnership with the Swedish Company Iconovo to create spray-dried formulations for an intranasal biologic utilizing Iconovo's ICOone Nasal device. This collaboration focuses on a reformulated substance aimed at obesity treatment.
________________________________________
Industry Outlook Scope:
By Device Type
• Liquid Nasal Spray Devices
o Metered-dose
o Non-metered
• Powder Nasal Devices
o Single Dose
o Multi Dose
• Pressurized Metered-Dose Inhalers (pMDIs)
o Breath-actuated
o Manual
• Nasal Dropper Devices
• Nasal Gel Applicators
• Nebulizing Nasal Devices
By Container Technology
• Pressurized Containers
• Non Pressurized Containers
By Usage Type
• Single-Use
• Reusable
By Therapeutic Application
• Respiratory Disorders
• Central Nervous System (CNS)
• Opioid Overdose / Emergency
• Pain Management
• Hormonal Therapies
• Vaccines & Infectious Disease
• Endocrine & Metabolic Disorders
• Others
________________________________________
Geographical Insights: Emerging Corridors of Growth
• Regional Overview: Europe's modern healthcare establishment and appealing patient awareness have led to a huge uptake of non-invasive therapy. Investments in healthcare and the rising incidence of neurological and respiratory conditions are driving the Asia-Pacific region's rapid growth. Alternative medication delivery systems are anticipated to rise consistently in growing regions with better healthcare infrastructure, such as Latin America and the Middle East and Africa.
• Countries to Watch: Germany and Switzerland are growing regions for their precise engineering and pharmaceutical innovation, whereas the U.S. leads in intranasal medication administration through research and revolutionary technology. China and India prioritise inexpensive production and nasal vaccines, whereas South Korea and Japan are acknowledged experts in smart nasal systems. Australia and Canada make contributions through improved clinical research and regulatory support.
________________________________________
Regulatory Environment and Policy Support
• Government Regulations & Supportive Policies: Several government policies and regulations accelerate the market by enacting the quality framework for the manufacturing and approval of the devices. For instance, in Europe, the European Medicines Agency (EMA) and national regulatory bodies enforce the EU Medical Device Regulation (MDR 2017/745), which supports clinical evaluation, CE marking (European Conformity), ensuring devices meet high safety and performance standards.
• Key Government Initiatives: The market growth is attributed by the initiatives Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme aims to stimulate the medica devices including intranasal drug delivery devices in India through a ₹5,000 crore investment. Focusing on R&D and manufacturing, PRIP promotes collaboration between academia, industry, and research institutions to expedite innovation and commercialization of indigenous devices, enhancing local manufacturing and reducing import dependency while improving accessibility in both domestic and international markets.
________________________________________
Competitive Landscape and Strategic Outlook
The market for intranasal drug delivery devices is moderately consolidated due to regional expansion and technical advancements, such as breath-powered and networked devices that improve patient compliance and dosage accuracy. Technological innovations including powder-based delivery methods, preservative-free formulations, and sensor-enabled sprays, are the main focus of the manufacturers for the growth of nasal drug device the sector. Global footprint is being strengthened by strategic partnerships with pharmaceutical companies and R&D investments.
Industry Competition:
• Aegis Therapeutics LLC
• Aptar Pharma Group
• AstraZeneca Plc
• Becton, Dickinson and Company
• GlaxoSmithKline Plc
• H&T Presspart Manufacturing Ltd.
• Johnson & Johnson, Inc.
• Merck & Co., Inc.
• Neurelis Inc
• Novartis AG
• OptiNose Inc
• Pfizer Inc.
• Teleflex Incorporated
• Vectura Group Plc.
• 3M
________________________________________
Analyst Perspective
The intranasal drug delivery devices market, is transitioning from simple droppers and basic sprays, which offered limited dosing accuracy and local symptom relief, to modern intranasal devices, including metered-dose, breath-actuated, and powder systems, provide precise dosing, improved bioavailability, preservative-free formulations, and expanded applications in CNS, pain, and vaccine therapies. These advancements will enhance patient compliance, will enable systemic and targeted delivery, and will drive rapid growth in the market.
________________________________________
What to Expect from Outlook:
1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global Intranasal Drug Delivery Devices Market.
2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global Intranasal Drug Delivery Devices Market.
3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.
4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Intranasal Drug Delivery Devices Market with a forecast for the decade by both market share (%) & revenue (USD Million).
1. Key
Findings
2. Introduction
2.1. Executive Summery
2.2. Regional Snapshot
2.3. Market Scope
2.4. Market Definition
3. Across
The Globe
3.1. Factors Affecting End Use Industries
3.2. Upcoming Opportunities
3.3. Market Dynamics
3.3.1. Ongoing Market Trends
3.3.2. Growth Driving Factors
3.3.3. Restraining Factors
3.4. Value Chain Analysis
3.4.1. List of Manufacturers
3.4.2. List of Distributors/Suppliers
3.5. PORTER’s & PESTLE Analysis
3.6. Key Developments
3.7. Key Industry Patents
4. Global
Intranasal Drug Delivery Devices Market Overview, By Device Type
4.1. Market Size (US$ Mn) Analysis, 2019 – 2034
4.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
4.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
4.3.1. Liquid Nasal Spray Devices
4.3.1.1. Metered-dose
4.3.1.2. Non-metered
4.3.2. Powder Nasal Devices
4.3.2.1. Single‑Dose
4.3.2.2. Multi‑Dose
4.3.3. Pressurized Metered-Dose Inhalers (pMDIs)
4.3.3.1. Breath-actuated
4.3.3.2. Manual
4.3.4. Nasal Dropper Devices
4.3.5. Nasal Gel Applicators
4.3.6. Nebulizing Nasal Devices
5. Global
Intranasal Drug Delivery Devices Market Overview, By Container Technology
5.1. Market Size (US$ Mn) Analysis, 2019 – 2034
5.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
5.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
5.3.1. Pressurized Containers
5.3.2. Non‑Pressurized Containers
6. Global
Intranasal Drug Delivery Devices Market Overview, By Usage Type
6.1. Market Size (US$ Mn) Analysis, 2019 – 2034
6.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
6.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
6.3.1. Single Use
6.3.2. Reusable
7. Global
Intranasal Drug Delivery Devices Market Overview, By Distribution Channel
7.1. Market Size (US$ Mn) Analysis, 2019 – 2034
7.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
7.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Online Pharmacies / eCommerce
7.3.4. Specialty Pharmacies
8. Global
Intranasal Drug Delivery Devices Market Overview, By Therapeutic Application
8.1. Market Size (US$ Mn) Analysis, 2019 – 2034
8.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
8.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
8.3.1. Respiratory Disorders
8.3.2. Central Nervous System (CNS)
8.3.3. Opioid Overdose / Emergency
8.3.4. Pain Management
8.3.5. Hormonal Therapies
8.3.6. Vaccines & Infectious Disease
8.3.7. Endocrine & Metabolic Disorders
8.3.8. Others
9. Global
Intranasal Drug Delivery Devices Market Overview, By Region
9.1. Market Size (US$ Mn) Analysis, 2019 – 2034
9.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
9.3. Market Absolute $ Opportunity Analysis,
2019 – 2034
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Middle East & Africa
9.3.5. South America
10. North
America Intranasal Drug Delivery Devices Market Overview
10.1. Market Size (US$ Mn) Analysis, 2019 – 2034
10.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
10.3. Market Absolute $ Opportunity Analysis, 2019
– 2034
10.3.1. By Country
10.3.1.1. U.S.
10.3.1.2. Canada
10.3.1.3. Mexico
10.3.2. By Device Type
10.3.3. By Container Technology
10.3.4. By Usage Type
10.3.5. By Distribution Channel
10.3.6. By Therapeutic Application
11. Europe
Intranasal Drug Delivery Devices Market Overview
11.1. Market Size (US$ Mn) Analysis, 2019 – 2034
11.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
11.3. Market Absolute $ Opportunity Analysis, 2019
– 2034
11.3.1. By Country
11.3.1.1. UK
11.3.1.2. Italy
11.3.1.3. Spain
11.3.1.4. Germany
11.3.1.5. France
11.3.1.6. Rest of Europe
11.3.2. By Device Type
11.3.3. By Container Technology
11.3.4. By Usage Type
11.3.5. By Distribution Channel
11.3.6. By Therapeutic Application
12. Asia
Pacific Intranasal Drug Delivery Devices Market Overview
12.1. Market Size (US$ Mn) Analysis, 2019 – 2034
12.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
12.3. Market Absolute $ Opportunity Analysis, 2019
– 2034
12.3.1. By Country
12.3.1.1. China
12.3.1.2. Japan
12.3.1.3. India
12.3.1.4. South Korea
12.3.1.5. Rest of Asia Pacific
12.3.2. By Device Type
12.3.3. By Container Technology
12.3.4. By Usage Type
12.3.5. By Distribution Channel
12.3.6. By Therapeutic Application
13. Middle
East & Africa Intranasal Drug Delivery Devices Market Overview
13.1. Market Size (US$ Mn) Analysis, 2019 – 2034
13.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
13.3. Market Absolute $ Opportunity Analysis, 2019
– 2034
13.3.1. By Country
13.3.1.1. GCC
13.3.1.2. South Africa
13.3.1.3. Rest of Middle East & Africa
13.3.2. By Device Type
13.3.3. By Container Technology
13.3.4. By Usage Type
13.3.5. By Distribution Channel
13.3.6. By Therapeutic Application
14. South
America Intranasal Drug Delivery Devices Market Overview
14.1. Market Size (US$ Mn) Analysis, 2019 – 2034
14.2. Market Share (%) Analysis (2023 vs 204),
Y-o-Y Growth (%) Analysis (2023-2034) & Market Attractiveness Analysis
(2024-2034)
14.3. Market Absolute $ Opportunity Analysis, 2019
– 2034
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Argentina
14.3.1.3. Rest of South America
14.3.2. By Device Type
14.3.3. By Container Technology
14.3.4. By Usage Type
14.3.5. By Distribution Channel
14.3.6. By Therapeutic Application
15. Country
Wise Market Analysis
15.1. Growth Comparison By Key Countries
16. Competitive
Landscape
16.1. Market Share (%) Analysis, By Top Players
16.2. Maret Structure Analysis, By Tier I & II
Companies
17. Company
Profiles
17.1. Aegis Therapeutics LLC
17.1.1. Company Overview
17.1.2. Business Segments
17.1.3. Financial Insights
17.1.4. Key Business Aspects (Noise Analysis)
17.2. Aptar Pharma Group
17.3. AstraZeneca Plc
17.4. Becton, Dickinson and Company
17.5. GlaxoSmithKline Plc
17.6. H&T Presspart Manufacturing Ltd.
17.7. Johnson & Johnson, Inc.
17.8. Merck & Co., Inc.
17.9. Neurelis Inc
17.10. Novartis AG
17.11. OptiNose Inc
17.12. Pfizer Inc.
17.13. Teleflex Incorporated
17.14. Vectura Group Plc.
17.15. 3M
18. Analysis
& Recommendations
18.1. Targeting Segment
18.2. Targeting Region
18.3. Market Approach
19. Research
Methodology
20. Disclaimer
